| BID | 122.40 | ASK | 122.58 | ||
| Open | 125.55 | Previous Close | 125.01 | ||
| Pre-Market | - | After-Market | 122.00 | ||
| - - | -0.57 -0.47% |
| Target Price | 155.86 | Analyst Rating | Strong Buy 1.07 | |
| Potential % | 27.16 | Finscreener Ranking | ★★★★ 55.19 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★ 47.28 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★+ 48.57 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Market Cap | 21.03B | Earnings Rating | Strong Buy | |
| Price Range Ratio 52W % | 58.36 | Earnings Date | 29th Jul 2021 |
Today's Price Range 120.25125.70 | 52W Range 70.75159.54 | 5 Year PE Ratio Range -54.20-13.40 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 2.83% | ||
| 1 Month | 26.70% | ||
| 3 Months | -6.17% | ||
| 6 Months | -3.74% | ||
| 1 Year | 36.82% | ||
| 3 Years | 78.86% | ||
| 5 Years | 989.51% | ||
| 10 Years | 1 558.59% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -25.08 | |||
ROE last 12 Months | -23.47 | |||
ROA (5Y Avg) | -4.81 | |||
ROA last 12 Months | -12.98 | |||
ROC (5Y Avg) | -22.70 | |||
ROC last 12 Months | -13.33 | |||
Return on invested Capital Q | -0.54 | |||
Return on invested Capital Y | -19.63 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 7.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -24.00 | ||||
| 5.73 | ||||
| 13.87 | ||||
| 174.80 | ||||
| -62.00 | ||||
| 0.70 | ||||
| -34.34 | ||||
| 21.27 | ||||
| 21.90B | ||||
| Forward PE | -49.34 | |||
| PEG | -2.03 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.60 | ||||
| 2.80 | ||||
| 0.36 | ||||
| 0.65 | ||||
| -10.70 | ||||
| Leverage Ratio | 1.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 75.20 | ||||
| -58.80 | ||||
| -48.00 | ||||
| -67.60 | ||||
| -49.66 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.55B | ||||
| 9.01 | ||||
| 64.13 | ||||
| 91.52 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2021 | -1.04 | -0.18 | 82.69 |
| Q04 2020 | -0.19 | -0.09 | 52.63 |
| Q03 2020 | -0.51 | -0.36 | 29.41 |
| Q02 2020 | -0.62 | -0.58 | 6.45 |
| Q01 2020 | -0.57 | -0.60 | -5.26 |
| Q04 2019 | -0.37 | -0.37 | 0.00 |
| Q03 2019 | -0.41 | -0.31 | 24.39 |
| Q02 2019 | -0.56 | -0.30 | 46.43 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2021 QR | -0.72 | 14.29 | Positive |
| 9/2021 QR | -0.75 | 1.32 | Positive |
| 12/2021 FY | -2.65 | 23.63 | Positive |
| 12/2022 FY | -2.47 | -8.81 | Negative |
| Next Report Date | 29th Jul 2021 |
| Estimated EPS Next Report | -0.72 |
| Estimates Count | 7 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.08M |
| Shares Outstanding | 171.55M |
| Trades Count | 18.93K |
| Dollar Volume | 221.33M |
| Avg. Volume | 1.67M |
| Avg. Weekly Volume | 1.38M |
| Avg. Monthly Volume | 1.54M |
| Avg. Quarterly Volume | 1.51M |
Exact Sciences Corporation (NASDAQ: EXAS) stock closed at 122.57 per share at the end of the most recent trading day (a -1.95% change compared to the prior day closing price) with a volume of 1.08M shares and market capitalization of 21.03B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 5000 people. Exact Sciences Corporation CEO is Kevin T. Conroy.
The one-year performance of Exact Sciences Corporation stock is 36.82%, while year-to-date (YTD) performance is -7.49%. EXAS stock has a five-year performance of 989.51%. Its 52-week range is between 70.75 and 159.54, which gives EXAS stock a 52-week price range ratio of 58.36%
Exact Sciences Corporation currently has a PE ratio of -24.00, a price-to-book (PB) ratio of 5.73, a price-to-sale (PS) ratio of 13.87, a price to cashflow ratio of 174.80, a PEG ratio of 2.32, a ROA of -12.98%, a ROC of -13.33% and a ROE of -23.47%. The company’s profit margin is -49.66%, its EBITDA margin is -48.00%, and its revenue ttm is $1.55 Billion , which makes it $9.01 revenue per share.
Of the last four earnings reports from Exact Sciences Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.72 for the next earnings report. Exact Sciences Corporation’s next earnings report date is 29th Jul 2021.
The consensus rating of Wall Street analysts for Exact Sciences Corporation is Strong Buy (1.07), with a target price of $155.86, which is +27.16% compared to the current price. The earnings rating for Exact Sciences Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Exact Sciences Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Exact Sciences Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 16.28, ATR14 : 5.35, CCI20 : 140.48, Chaikin Money Flow : 0.18, MACD : 2.29, Money Flow Index : 63.87, ROC : 10.23, RSI : 62.32, STOCH (14,3) : 83.51, STOCH RSI : 0.69, UO : 64.28, Williams %R : -16.49), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Exact Sciences Corporation in the last 12-months were: Daniel J. Levangie (Option Excercise at a value of $183 398), Daniel J. Levangie (Sold 19 730 shares of value $1 854 620 ), Graham Lidgard (Option Excercise at a value of $1 226 915), Graham Lidgard (Sold 67 076 shares of value $8 715 098 ), James E. Doyle (Sold 7 078 shares of value $737 552 ), Jeffrey T. Elliott (Option Excercise at a value of $1 921 599), Jeffrey T. Elliott (Sold 67 980 shares of value $7 344 133 ), Katherine S. Zanotti (Option Excercise at a value of $358 334), Katherine S. Zanotti (Sold 64 386 shares of value $6 818 425 ), Kevin T. Conroy (Option Excercise at a value of $99 995), Kevin T. Conroy (Sold 282 856 shares of value $34 626 224 ), Michael Stephen Wyzga (Option Excercise at a value of $272 714), Michael Stephen Wyzga (Sold 19 021 shares of value $2 474 822 ), Sarah Condella (Option Excercise at a value of $0), Sarah Condella (Sold 5 867 shares of value $811 053 ), Scott D. Coward (Option Excercise at a value of $591 745), Scott D. Coward (Sold 48 035 shares of value $6 562 421 ), Thomas D. Carey (Option Excercise at a value of $288 658), Thomas D. Carey (Sold 61 240 shares of value $5 756 560 ), Torsten Hoof (Option Excercise at a value of $248 568), Torsten Hoof (Sold 12 365 shares of value $1 028 224 )
Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.
CEO: Kevin T. Conroy
Telephone: +1 608 284-5700
Address: 441 Charmany Drive, Madison 53719, WI, US
Number of employees: 5 000
